Fennec Pharmaceuticals Inc  

(Public, TSE:FRX)   Watch this stock  
Find more results for TSE:AHX
-0.04 (-2.60%)
Nov 27 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 1.50 - 1.53
52 week 1.50 - 3.55
Open 1.53
Vol / Avg. 300.00/3,716.00
Mkt cap 16.42M
P/E 8.83
Div/yield     -
EPS 0.17
Shares 10.94M
Beta -0.03
Inst. own     -
Nov 12, 2015
Q3 2015 Fennec Pharmaceuticals Inc Earnings Release

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -29.71% -105.53%
Return on average equity -46.30% -
Employees 1 -
CDP Score - -


68 Tw Alexander Drive PO Box 13628
DURHAM, NC 27709-3628
United States - Map
+1-919-6364530 (Phone)
+1-919-8900490 (Fax)

Website links


Fennec Pharmaceuticals Inc., formerly Adherex Technologies Inc. is a biopharmaceutical company focused on cancer therapeutics. The Company’s lead products both of which are in the clinical stage of development include Sodium Thiosulfate (STS), a water soluble thiol compound that acts as a chemical reducing agent, in two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children, and Eniluracil (EU), an oral irreversible dihydropyrimidine dehydrogenase (DPD) inhibitor, the enzyme responsible for rapidly breaking down 5-FU, completed a Phase II clinical trial in metastatic breast cancer. The Company has three wholly owned subsidiaries: Oxiquant, Inc., Adherex, Inc. and Cadherin Biomedical Inc.

Officers and directors

Rostislav Raykov Chairman of the Board, Chief Executive Officer
Age: 39
Robert C. Andrade Chief Financial Officer
Age: 39
Adrian J. Haigh Independent Director
Age: 56
Khalid Islam Independent Director
Age: 59
Chris A. Rallis Independent Director
Age: 61
Steven D. Skolsky Independent Director
Age: 59